Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Non-small Cell Lung Cancer (NSCLC): early-phase trial registry
30 of 60 indexed Non-small Cell Lung Cancer (NSCLC) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #235 of 28,707 conditions by registered trial count.
60 US clinical trials · 30 currently recruiting · #235 of 28,707 conditions by registered trial count
Non-small Cell Lung Cancer (NSCLC): 60 US clinical trials tracked, 30 recruiting.
Non-small Cell Lung Cancer (NSCLC) is the subject of 60 registered US clinical trials on ClinicalTrials.gov, 30 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 48 in Phase 1-2 (earlier-stage). The most active sponsor is Revolution Medicines, running 7 of these trials.
Enrollment posture brief
Registry condition non-small-cell-lung-cancer-nsclc
OPEN 30 | RECR 50% | LATE 9 | EARLY 48 | RANK #235 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Non-small Cell Lung Cancer (NSCLC) lists 30 open slots (50% of 60 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Non-small Cell Lung Cancer (NSCLC) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Non-small Cell Lung Cancer (NSCLC) is recruiting above its size-band peers.
30 of 60 indexed trials (50%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Non-small Cell Lung Cancer (NSCLC) trials is spread across many organizations.
Revolution Medicines accounts for 7 of 60 trials (11.7%). 43 distinct sponsors appear on at least one study for this condition label.
-
Typical Non-small Cell Lung Cancer (NSCLC) enrolment sits around 209 participants.
Median target enrolment is 209 among the 60 trials that report a genuine target (sentinel values excluded). 23 of those (38.3%) plan for fewer than 100 participants.
-
Non-small Cell Lung Cancer (NSCLC) research is mostly interventional.
59 interventional and 1 observational studies make up this index (98.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
60 total, page 1 of 2
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Exelixis
NCT05176483
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Revolution Medicines
NCT05379985
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Amgen
NCT05920356
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Revolution Medicines
NCT06162221
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Merck Sharp & Dohme
NCT06170788
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Revolution Medicines
NCT06040541
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Revolution Medicines
NCT07349537
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Merck Sharp & Dohme
NCT06074588
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Revolution Medicines
NCT06128551
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
Merck Sharp & Dohme
NCT06305754
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
AstraZeneca
NCT07291037
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Revolution Medicines
NCT07397338
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics
NCT05107674
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Kura Oncology
NCT06026410
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Bristol-Myers Squibb
NCT07223047
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
EMD Serono Research & Development Institute
NCT06710132
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
Bristol-Myers Squibb
NCT06476808
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Genmab
NCT07288177
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals
NCT05985655
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Sutro Biopharma
NCT07227168
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Nuvation Bio
NCT07154706
Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
Pierre Fabre Medicament
NCT06567015
Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy
The Cooper Health System
NCT06688422
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
LG Chem
NCT06332755
Pembrolizumab for Advanced NSCLC and PS 2-3
Icahn School of Medicine at Mount Sinai
NCT05589818
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Astellas Pharma Global Development
NCT07140016
Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer
Integro Theranostics
NCT07276789
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Olivera Finn
NCT01720836
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America
NCT06943521
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
Radiopharm Theranostics
NCT05799274
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
AstraZeneca
NCT03164616
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
AstraZeneca
NCT03775486
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
NCT04083599
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
Replimune
NCT03767348
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
Daiichi Sankyo
NCT03260491
Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%
Bristol-Myers Squibb
NCT07215962
HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer
Daiichi Sankyo
NCT04676477
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines
NCT05462717
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Immuneering Corporation
NCT05585320
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
ArriVent BioPharma
NCT05364073
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
AbbVie
NCT03893955
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
Servier Bio-Innovation
NCT06162572
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
AbbVie
NCT04721015
An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
AbbVie
NCT04189614
PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung
Duke University
NCT05553834
Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC
University of Texas Southwestern Medical Center
NCT03667820
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Arcus Biosciences
NCT05891171
Prospective Clinicogenomic Program
Genentech
NCT04180176
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
Bristol-Myers Squibb
NCT04026412
A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
PharmaMar
NCT01951157
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 37 |
| Phase 2 | 11 |
| Phase 3 | 8 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Non-small Cell Lung Cancer (NSCLC) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Non-small Cell Lung Cancer (NSCLC) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Non-small Cell Lung Cancer (NSCLC) page
60 registered trials, 30 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 30 Non-small Cell Lung Cancer (NSCLC) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Revolution Medicines sponsors the most Non-small Cell Lung Cancer (NSCLC) trials on record, review their full trial history before evaluating a specific study. See Revolution Medicines's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-small Cell Lung Cancer (NSCLC) condition card totals 60 registered trials; most-linked intervention Pembrolizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.